September 29, 2026 · High impact · Updated Sep 29, 2026
Viking Therapeutics (VKTX) recently completed a $548 million capital raise, exceeding its initial $400 million target due to underwriters fully exercising their options. Despite a three-day stock losing streak, retail investors view the dip as a buying opportunity, fueled by ongoing buyout speculation.
AlphaOS aggregates and analyzes market news to extract structured investment intelligence. Content is for research and education only — not investment advice.
This week
2 of 24 shown
See the full board →Connected companies and research pages from the AlphaOS knowledge graph.